Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

11.1%

2 terminated out of 18 trials

Success Rate

85.7%

-0.8% vs benchmark

Late-Stage Pipeline

22%

4 trials in Phase 3/4

Results Transparency

42%

5 of 12 completed with results

Key Signals

5 with results86% success

Data Visualizations

Phase Distribution

13Total
Not Applicable (6)
P 2 (3)
P 3 (4)

Trial Status

Completed12
Recruiting2
Terminated2
Unknown1
Enrolling By Invitation1

Trial Success Rate

85.7%

Benchmark: 86.5%

Based on 12 completed trials

Clinical Trials (18)

Showing 18 of 18 trials
NCT03835312Not ApplicableRecruiting

Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM

NCT03478670Enrolling By InvitationPrimary

Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)

NCT00598481Phase 2CompletedPrimary

ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID

NCT02735824RecruitingPrimary

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies

NCT02554630Completed

Novel Mechanisms and Approaches to Treat Neonatal Sepsis

NCT02783482Phase 3CompletedPrimary

Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency

NCT04798677Not ApplicableCompleted

Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine

NCT03920735Unknown

Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients

NCT00176865Phase 2Completed

Stem Cell Transplant for Immunologic or Histiocytic Disorders

NCT00811174Phase 3TerminatedPrimary

Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases

NCT02630082Not ApplicableCompleted

Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru

NCT00468273Phase 3CompletedPrimary

A Clinical Study of Intravenous Immunoglobulin

NCT01727895Not ApplicableCompletedPrimary

Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans

NCT00006054Not ApplicableTerminatedPrimary

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

NCT00001158CompletedPrimary

Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System

NCT00001438Phase 2Completed

A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes

NCT00001646Phase 3Completed

Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis

NCT00006131Not ApplicableCompleted

Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster

Showing all 18 trials

Research Network

Activity Timeline